Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kotai Biotechnologies Inc. maintains a patent portfolio currently active in the Biotechnology & Pharmaceuticals technology area. The prosecution landscape is characterized by concentration, as evidenced by the 1 pending office action currently assigned to 1 distinct examiner. This examiner, SPENCE, JENNIFER SUZANNE, is the busiest examiner for the portfolio and manages the 1 pending office action currently requiring a response.
The involvement of 1 distinct art unit indicates that the company's current legal efforts are focused on a specific technical field. For the practitioner, this means that the outcome of the pending matter will be determined by the interpretation of SPENCE, JENNIFER SUZANNE. Understanding the preferences of this 1 examiner is the primary task for managing the portfolio's current growth. The lack of multiple pending actions or diverse art units simplifies the immediate administrative burden but increases the impact of this individual examination process on the company's intellectual property goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259687 | METHOD FOR PRODUCING REGENERATED T CELL VIA IPS CELL | SPENCE, JENNIFER SUZANNE | 15d overdue |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18259687 | METHOD FOR PRODUCING REGENERATED T CELL VIA IPS CELL | SPENCE, JENNIFER SUZANNE | 1633 | §102§103§112DP | Final Rejection | 15d overdue | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial